Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Microbiota 15 - April 2022
  3. Gut Microbiota #15
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 15 - April 2022
  3. Gut Microbiota #15
Gastroenterology

Gut Microbiota #15

Cancer

By Pr. Markku Voutilainen
Turku University Faculty of Medicine; Turku University Hospital, Department of Gastroenterology, Turku, Finland

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

About this article

Author

Voutilainen Markku Prof Markku Voutilainen
Created 22 April 2022
Updated 12 August 2024

GUT MICROBIOTA MODULATES RESPONSE TO PROSTATE CANCER TREATMENT

Pernigoni N, Zagato E, Calcinotto A, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 2021 Oct 8;374(6564):216-224.

Prostate cancer (PC) is one of the most common cancers in males. Because tumors growth and progression depend on androgen levels, androgen deprivation therapy (ADT), surgical or chemical castration is used to treat patients with PC. However, some of them develop a castration- resistant prostate cancer (CRPC) which result in tumor progression and new treatment strategy are under investigation. Since recent studies have highlighted the role of microbiota in both cancer development and therapy success, the authors used PC mouse models and patient data to examine the role of gut microbiota in PC carcinogenesis. Enrichment of Ruminococcus spp. and Bacteroides acidifaciens was detected after development of CRPC but gut microbiota ablation slowed tumor growth in CRPC mice. Castration resistant (CR) fecal microbiota transplantation (FMT) from castration-resistant (CR) mice and R. gnavus administration led to increased circulating androgen levels and increased PC growth and CRPC development. PC growth was controlled by FMT from hormone sensitive PC individuals and Prevotella stercorea administration. CRPC patients had enrichment of Ruminococcus and Bacteroides genera associatied with poor outcome while hormone- sensitive PC patients had higher abundance of Prevotella genus linked with more favorable outcome.

Commensal gut microbiota in androgen- deprived patients and mice produce androgens that promote PC growth and the development of CRPC via systemic circulation. Modulation of gut microbiota could theoretically be used as additional therapy for PC.

THE ASSOCIATION BETWEEN GUT DYSBIOSIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Li N, Dai Z, Wang Z, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respir Res 2021 Oct 25;22(1):274.

Chronic obstructive pulmonary disease (COPD) refers to lung diseases (emphysema, bronchitis and asthma) characterized by progressive respiratory distress. Recent studies have revealed changes in the gut microbiota linked to disease development in the lungs. While primarily considered a respiratory disease, COPD commonly co-occurs with chronic gastrointestinal tract diseases. In the present study, the authors took an interest in the the gut-lung axis linked to COPD. Stool analyses have revealed that patients with severe COPD had lower abundance of Bacteroidetes but higher abundance of Firmicutes. Of bacterial families, Prevotellaceae abundance was higher in mild COPD, whereas Bacteroidaceae and Fusobacteriaceae abundancies were lower in severe COPD compared to healthy controls. Short chain fatty acid (SCFA) levels were significantly lower in severe COPD. Fecal microbiota transfer (FMT) to mice from COPD patients caused a significant weight reduction and airway mucus hypersecretion in mice. Acceleration of lung function decline was detected in FMT mice during biomass smoke exposure. This study revealed that COPD patients have gut microbiota dysbiosis with reduced SCFA levels. These changes are possibly linked to airway inflammation and COPD progression.

THE IMPACT OF COMEDICATION ON THE TREATMENT EFFICACY OF IMMUNE CHECKPOINT INHIBITORS

Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse effects. Eur J Cancer 2021 Nov;157:474-484.

Immune checkpoint inhibitors (ICI) have dramatically improved the prognosis of several advanced cancers. Evidence have shown that gut microbiota may modulate the treatment response for ICI, and may also be involved in the pathogenesis of immune-related adverse events (IRAE). While antibiotics are known to deteriorate the prognosis of ICI treated cancer patients, little is known about the effect on the microbiota of various co-medications when given at ICI initiation. In the present study, the authors examined the effect of co-medications given 1 month before or after administration of ICI therapy on the treatment results and the occurrence of IRAE.

The use of antibiotics, glucocorticoids (daily dose > 10 mg), proton pump inhibitors, psychotropic drugs, morphine and insulin were associated with significantly shortened survival and decreased tumor response. Combination therapy with these drugs decreased survival more than monotherapy. These medications were also associated with decreased incidence of IRAE. Co-administration of statins, angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, non-steroidal anti-inflammatory drugs, aspirin and oral antidiabetic drugs did not impact patient survival. The present study showed that co-medication influences both to the response and IRAE of ICI treatment. The impact of co-medication may be mediated via microbiota or other immunomodulatory mechanisms. In clinical practice, baseline co-medications should be carefully assessed when ICI therapy is planned. Drugs with negative impact on ICI therapy should be avoided when possible.

Tags
Gut microbiota Microbiome Flora
    Focus
    Microbiota 15 - April 2022
    • Overview
      • New perspectives in autism: the role of microbiota in social communication
      • Microbiota in Covid-19 pandemic
    • Commented article
      • Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours
      • Early-life formula feeding is associated with gut microbiota alterations and increased antibiotic resistance in infants
    • Congress review
      • Microbiome topics at GASTRO 2021
    • Press review
      • Gut Microbiota #15
      • Vaginal Microbiota #15
    • Expert opinion
      • The blue poop challenge a reliable method to evaluate gut transit?
    Created 22 April 2022
    Updated 12 August 2024

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Content type

    Article

    Author

    Voutilainen Markku Prof Markku Voutilainen
    Microbiome topics at GASTRO 2021
    Vaginal Microbiota #15
    Focus

    Microbiota 15 - April 2022

    Overview

    New perspectives in autism: the role of microbiota in social communication Microbiota in Covid-19 pandemic

    Commented article

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours Early-life formula feeding is associated with gut microbiota alterations and increased antibiotic resistance in infants

    Congress review

    Microbiome topics at GASTRO 2021

    Press review

    Gut Microbiota #15 Vaginal Microbiota #15

    Expert opinion

    The blue poop challenge a reliable method to evaluate gut transit?
    Gastroenterology
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo